Remidazolam besylate, a new anesthetic drug of humanwell pharmaceutical, 1.1, has been successfully approved

According to the information on June 17 on the website of the State Food and Drug Administration (CFDA), the acceptance status of humanwell Pharmaceutical (600079) class 1.1 new drug rimazazolam besylate and rimazazolam besylate for injection was changed to "certificate preparation completed - pending approval document", or clinical approval was successfully obtained Yichang humanwell insiders told the big smart news agency that the company has not yet received the approval, but the approval is basically OK After receiving the approval, organize the next work as soon as possible It is understood that remazolam benzenesulfonate of Yichang humanwell Pharmaceutical (600079), a holding subsidiary of humanwell, is used for surgical anesthesia Yichang humanwell has undertaken the R & D, production and sales of humanwell Pharmaceutical (600079) narcotic analgesics In 2014, the sales revenue of humanwell Yichang was 1528652500 yuan, accounting for 21.68% of the business revenue According to some data, in 2013, the market scale of anesthetics in sample hospitals in 16 cities in China reached 1.4 billion yuan, an increase of 8.31% over the previous year, and the anesthesia industry has maintained a high compound growth rate in the past few years In the field of anesthetics, it is divided into intravenous injection and inhalation type according to the way of administration Intravenous injection is mainly used in China and Europe, while inhalation type is mainly used in North America Humanwell Pharmaceutical (600079) is mainly engaged in the pharmaceutical industry, and its market segments include anesthetics, analgesics, birth control drugs, blood products, Uygur nationality drugs, etc In the field of narcotic drugs in China, humanwell Pharmaceutical (600079) is a leading enterprise, and its market share of narcotic drugs ranks first in China.